The scoop
Each vial contains 15 mg of lyophilized tirzepatide. Tirzepatide is a dual GIP/GLP-1 receptor agonist, supplied as a powder cake under a sealed cap. Want another size? The tirzepatide family page lists all eight fills. Laboratory research only, adults 21+, never for people or pets. Stay frosty.
Sizing up the 15mg vial
The 15mg vial sits at rung 3 of 8 in our Tirzepatide lineup, somewhere between the 5mg and 120mg fills. Its 15 mg of freeze-dried powder costs $45.00, or $3.00 per mg: 40% less per mg than the 5mg vial, and 50% more per mg than the 120mg vial.
One size down, the 10mg vial holds 5 mg less and costs $10.00 less. One size up, the 20mg vial adds 5 mg for $5.00 more, so each extra milligram costs $1.00. Per milligram, the 20mg vial comes in at $2.50, versus $3.00 here. Stacking 3 of the 5mg vials would give you the same 15 mg as this one vial: $75.00 at single-vial prices, versus $45.00 here.
Quick numbers
| Fill | 15mg |
|---|
| Vial price | $45.00 |
|---|
| Price per mg | $3.00 |
|---|
| Spot in the range | 3 of 8 by fill (mid-range) |
|---|
| Powder per $10 | 3.3 mg |
|---|
| Share of the 120mg fill | 13% |
Price per mg across the Tirzepatide range
- 5mg: $5.00/mg · 67% more per mg
- 10mg: $3.50/mg · 17% more per mg
- 15mg: $3.00/mg · this vial
- 20mg: $2.50/mg · 17% less per mg
- 30mg: $2.50/mg · 17% less per mg
- 40mg: $2.38/mg · 21% less per mg
- 60mg: $2.33/mg · 22% less per mg
- 120mg: $2.00/mg · 33% less per mg
All math uses today's single-vial prices from our shelf; the pack deals above can push the per-mg cost lower.
Spec sheet
| SKU | SR-TZ15 |
|---|
| Fill | 15mg |
|---|
| Form | Freeze-dried (lyophilized) powder, sealed vial |
|---|
| Shipping | Free US shipping on every order, $40 flat worldwide, tracked, usually ships within 24 hours |
Not FDA-approved. Snowman Research is a retailer, not a pharmacy. Sold for laboratory research only, never for human or veterinary use. See the research-use policy.
Tirzepatide GIP/GLP-1 dual agonist research peptide: an overview
Tirzepatide opened a new chapter in incretin research by engaging two receptors at once; it is supplied here as tirzepatide lyophilized powder for laboratory study. Here's a calm look at the headline studies.
Please note: Snowman Research does not offer dosing information or usage guidance of any kind. Everything we list, this item included, is sold strictly for research purposes and nothing else.
Published findings
Tirzepatide has been tested in large randomized human trials. The 72-week SURMOUNT-1 study (NEJM, 2022) in adults with obesity reported average weight changes between −15.0% and −20.9% depending on dose level, compared with −3.1% for placebo [1]. SURPASS-2 (NEJM, 2021) compared tirzepatide head-to-head with semaglutide in type 2 diabetes and found it noninferior and superior for lowering glycated hemoglobin over 40 weeks [2]. In SURMOUNT-OSA (NEJM, 2024), people with obesity and moderate-to-severe obstructive sleep apnea saw their apnea-hypopnea index drop by roughly 25 to 29 events per hour at one year, against about 5 with placebo [3].
Mechanism at a glance
Tirzepatide is a single peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor, two hormones released from the intestine. That makes it a dual GIP/GLP-1 receptor agonist [4].
Regulatory & WADA notes
The FDA has approved tirzepatide for blood-sugar control in adults with type 2 diabetes and, on November 8, 2023, for chronic weight management [4]. This research material is separate from those approved medicines. Tirzepatide isn't on WADA's 2026 Prohibited List, though WADA's 2026 Monitoring Program follows markers of semaglutide and tirzepatide [5].
Thanks for reading. Stay warm, and keep your bench notes tidy.
Further reading
- Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. PMID 34170647. https://pubmed.ncbi.nlm.nih.gov/34170647/
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205. PMID 38912654. https://pubmed.ncbi.nlm.nih.gov/38912654/
- FDA Approves New Medication for Chronic Weight Management. U.S. Food and Drug Administration press announcement, Nov 8, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
- The 2026 Monitoring Program. World Anti-Doping Agency, 2026 Monitoring Program. https://www.wada-ama.org/sites/default/files/2025-09/2026_list_monitoring_program_en_final_clean_september_2025.pdf
For laboratory research use only. This product is not intended for human or veterinary use and is not an FDA-approved drug; nothing on this page is medical advice. You must be 21 or older to purchase.
Pass it on
Share this vial with your personal link. Guests who buy credit the last link they clicked;
accounts created through your link stay linked to you. You earn 10% cash
of the product total (shipping excluded) on every paid order, or 20% as store credit.
Sign in or
make a free account to get your link.
How Snowball rewards work